LONG-TERM RESULTS OF TREATING PATIENTS WITH BONE OSTEOSARCOMA TAKING INTO ACCOUNT THE CONTENT OF MATRIX METALLOPROTEINAS AND THEIR TISSUE INHIBITORS IN BLOOD SERUM